Agilent Technologies has announced a cash deal to acquire digital pathology software firm Proscia for $240 million. The agreement, which includes a potential $30 million performance-based bonus, marks a strategic shift for the company toward AI-enabled diagnostics. Investors are focusing on how the firm integrates this software-heavy business into its existing hardware portfolio to build recurring revenue streams.
Agilent Technologies is expanding its digital capabilities by acquiring Proscia, a developer of AI-powered pathology software, for $240 million in cash. The agreement also includes an additional $30 million in payments contingent upon Proscia meeting specific future performance goals. This acquisition is part of a broader move by the company to evolve its business model.
For years, Agilent has been primarily known for its laboratory hardware. By bringing Proscia’s technology in-house, the company aims to create an integrated ecosystem where its physical diagnostic tools are paired with advanced digital image analysis. The two companies are not strangers; they established a distribution partnership in 2022. This acquisition effectively takes that collaboration to the next level, allowing Agilent to own the full software-based workflow that pathologists use to analyze medical images.
Proscia’s software, which is currently used in thousands of laboratories, generated over $18 million in revenue over the last year. While this is a small portion of Agilent's total revenue, the strategic value lies in shifting toward a service-based model. By adding software-as-a-service (SaaS) features to its offerings, the company hopes to secure more stable and recurring revenue compared to traditional equipment sales.
Despite the growth potential, the acquisition comes with typical corporate risks. The most immediate concern for investors is execution. Integrating a software firm into a large-scale manufacturing operation is often complex. If the process encounters delays or if the integration costs exceed the initial budget, it could place pressure on company margins. Additionally, the AI diagnostics market is highly competitive, and the company must successfully scale Proscia’s technology to ensure it justifies the acquisition price.
The transaction is expected to close early in Agilent’s fiscal year 2027, provided it clears standard closing conditions. For now, the key monitorable for shareholders will be management's commentary on integration costs and the timeline for rolling out these combined diagnostic solutions to the global market.